The 2022 Hurun Rich List is announced, and 11 medical professionals are in the top 100!

【Pharmaceutical Network Industry News】On November 8, Hurun Research Institute released the "2022 Hurun Report", which showed that a total of 1,305 entrepreneurs with personal wealth of more than 5 billion yuan appeared on this year's Hurun Report, a decrease of 11%
compared with last year.
The total wealth of entrepreneurs on the list was 24.
5 trillion yuan, down 18%
from last year.
From the ranking of the list, the 68-year-old Zhong of Yangshengtang has once again become China's richest man, and his wealth has increased by 17% from last year to 455 billion yuan
.
They were followed by Zhang Yiming, 39, of ByteDance, and Zeng Yuqun, 54 years old of CATL, with wealth of 245 billion yuan and 230 billion yuan
respectively.
Among the top 100 entrepreneurs on this year's list, 11 are mainly involved in the pharmaceutical field, including 68-year-old Zhejiang businessman Zhong Juan, 71-year-old Li Xiyan of Mindray, 60-year-old Xu Hang of Mindray and Perry, Chen Bang of Aier Ophthalmology, 57-year-old Chen Bang of Aier Ophthalmology, Jiang Rensheng family of Zhifei Biotechnology, Xu Haoyu family of Yangtze River Pharmaceutical, Zhu Bao national family of Health Yuan, Sun Piaoyang, 64 years old of Hengrui, Zhong Huijuan, 61 years old of Hansen, Zhao Yan family of Huaxi International, and Jian Jun
, 59 years old of Amec 。 Among them, in addition to Zhong Juan, there are also Li Xiyan and Xu Hang from Mindray with a wealth of more than 100 billion yuan, both with a wealth of 110 billion yuan, and the wealth of Chen Bang of Aier Ophthalmology will also approach 100 billion, reaching 95 billion yuan
.
Judging from the top 100 pharmaceutics, most of their main business companies are in medical devices, medical services, vaccines, medical cosmetology and other high-prosperity segments, and their performance since this year is relatively bright
.
For example, Mindray Medical, a leading domestic medical device company, belongs to the medical device industry, and under the trend of new domestic medical infrastructure, the company has obtained a more satisfactory performance "answer sheet"
.
According to the third quarterly report of 2022, the company's operating income in the first three quarters of Mindray was 23.
296 billion yuan, a year-on-year increase of 20.
13%; the net profit attributable to the parent was 8.
102 billion yuan, a year-on-year increase of 21.
60%; The non-net profit attributable to the mother was 8.
004 billion yuan, a year-on-year increase of 22.
30%.

Among them, in the third quarter alone, the company achieved operating income of 7.
940 billion yuan, a year-on-year increase of 20.
07%; the net profit attributable to the parent was 2.
815 billion yuan, a year-on-year increase of 21.
40%; The net profit of non-attributable parent was 2.
757 billion yuan, a year-on-year increase of 23.
35%.

Aier Ophthalmology, the leading company in the ophthalmic track, also achieved both revenue and net profit growth
.
The company's third quarterly report in 2022 shows that in the first three quarters, the operating income was 13.
052 billion yuan, a year-on-year increase of 12.
55%, and the net profit attributable to the parent was 2.
357 billion yuan, a year-on-year increase of 17.
65%.

At the investor conference call held on the evening of November 7, the company's senior management team said that some hospital operations were affected by the epidemic, but the growth of the company's refractive and optometry businesses is expected to continue, and the 1+8+N strategy is advancing in an orderly manner
.
The strategy refers to the construction of 1 world-class eye hospital, Changsha Aier; Build 8 national ophthalmic centers, namely Beijing, Shanghai, Guangzhou, Shenzhen, Wuhan, Shenyang, Chengdu and Chongqing; N represents the hospitals of provincial capital-level cities, which must reach the local first-class level
.
Although Hengrui's revenue and net profit attributable to the parent fell by 21.
06% and 24.
57% year-on-year in the first three quarters, Hengrui achieved revenue of 5.
717 billion yuan in the third quarter, an increase of 20.
38%
from the previous quarter.
At the same time, the company also received a significant increase in the position of funds under Gülen's management, and its holdings increased from 33.
3829 million in the second quarter to 75.
5398 million
.
The analysis believes that in the medium and long term, innovation is still the general trend of the pharmaceutical industry, and in the context of the current large number of clinical needs not being fully met, there is huge
room for growth in innovative drugs, innovative devices, medical services and consumer medicine.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.